Overall, the proposed combination therapy, facilitated by novel albumin-based NPs and a PLGA-PEG-PLGA hydrogel, represents a promising advancement in pancreatic cancer treatment, offering a balance between therapeutic effectiveness and reduced systemic impact. This evidence concerns the gene ALB and familial pancreatic carcinoma.